Business Context and Reporting Period
Company: Varex Imaging Corporation (VREX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year 2025 (53-week period ended October 3, 2025)
Business Overview: Varex is a leading designer and manufacturer of X-ray imaging components, including X-ray tubes, flat panel detectors, and linear accelerators. The company operates two segments: Medical (components for diagnostic imaging systems) and Industrial (security inspection, non-destructive testing, and irradiation systems). Approximately 70% of revenue is generated from international customers.
Key Financial Metrics
| Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenues, Net | $844.6 | $811.0 | +4% |
| Gross Profit | $290.5 | $256.9 | +13% |
| Total Gross Margin | 34.4% | 31.7% | +270 bps |
| Operating Expenses | $318.3 | $224.8 | +42% |
| Operating (Loss) Income | $(27.8) | $32.1 | Turn to Loss |
| Net (Loss) Income | $(69.9) | $(48.3) | Worsened |
| Diluted EPS | $(1.70) | $(1.20) | Worsened |
| Operating Cash Flow | $41.7 | $47.3 | -$5.6M |
| Total Debt (Principal) | $369.9 | $446.5 | -$76.6M |
| Cash & Equivalents | $145.0 | $168.7 | -$23.7M |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 4% to $844.6 million. The Medical segment grew 2% ($592.6M), driven by CT, oncology, and mammography sales. The Industrial segment grew 10% ($252.0M), driven by security inspection products and X-ray tubes.
- Goodwill Impairment: A non-cash goodwill impairment charge of $93.9 million was recorded in the Medical reporting unit during the third quarter. This was triggered by a sustained decline in stock price, reduced market capitalization, and downward revisions to long-term forecasts due to tariffs and trade investigations.
- Margin Expansion: Despite the impairment, gross margin improved to 34.4% from 31.7%, aided by favorable product mix, lower material costs, and improved productivity.
- Debt Restructuring: The company repaid $200.0 million in Convertible Senior Unsecured Notes at maturity in June 2025. This was partially funded by issuing $125.0 million in additional Senior Secured Notes in December 2024. Total debt principal decreased to $369.9 million.
- Inventory Build: Cash used for inventories increased by $46.5 million compared to the prior year, reflecting a strategic build-up for anticipated future demand.
Guidance, Outlook, Risks, and Unusual Items
- Trade and Tariff Risks: The company faces significant headwinds from U.S.-China trade tensions. New tariffs imposed in calendar year 2025 have increased costs and reduced competitiveness. The company is pursuing local-for-local manufacturing strategies to mitigate these impacts.
- MOFCOM Investigations: In April 2025, China's Ministry of Commerce initiated investigations into imported X-ray tubes and CT tube inserts. These were temporarily suspended in May and August 2025, and indefinitely suspended in November 2025. If recommenced, they could negatively impact the business.
- Legal Proceedings: Ongoing disputes exist regarding a joint venture in Germany (VEC Imaging) and a joint venture in Saudi Arabia. A German court ruled in October 2025 that neither party had been validly excluded from the VEC joint venture, though appeals are possible.
- Accounting Revision: The company corrected an error related to deferred tax assets and liabilities in prior periods. The correction was not material individually but required restatement of prior period financial statements.
- Liquidity: As of October 3, 2025, the company had $154.8 million available under its Revolving Credit Facility. Management believes current liquidity is sufficient for the next 12 months.
Key Facts for Investor Verification
- Goodwill Impairment Sustainability: Verify if the $93.9 million impairment charge is a one-time event or if further impairments are likely given the continued trade war environment and stock price volatility.
- Tariff Mitigation Effectiveness: Assess the success of the "local-for-local" manufacturing strategy in offsetting the cost increases from U.S.-China tariffs.
- MOFCOM Investigation Status: Monitor the status of the indefinitely suspended Chinese investigations; a recommencement could materially impact the Medical segment's revenue in China (approx. 10% of total revenue).
- Customer Concentration: The top five customers accounted for 40% of revenue, with Canon Medical Systems alone representing 18%. Verify the stability of these key OEM relationships.
- Debt Covenants: Confirm compliance with the consolidated fixed charge coverage ratio (minimum 1.25:1) and total net leverage ratio (maximum 3.75:1 for the current period) under the Revolving Credit Facility.